The Very Large Database of Lipids
NCT01698489 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 5051467
Last updated 2026-05-08
Summary
Closer examination of granular lipid data in a large population offers numerous opportunities to generate new knowledge, ranging from studies examining concordance between commonly used lipid parameters to phenotypic characterization of rare or extreme disorders of lipid metabolism, opening possibilities to better personalize future treatment of abnormal blood lipids.
STUDY POPULATION:
The Very Large Database of Lipids (VLDL) includes adults and children who were clinically referred for a Vertical Auto Profile (VAP). Patient samples originated predominantly from outpatient primary care clinics in the U.S. (85%), along with specialty clinics and inpatient settings.
LIPID MEASUREMENTS:
The VAP test (VAP Diagnostics Lab, Birmingham, Alabama, USA) directly measures cholesterol concentrations of low density lipoprotein, very low density lipoprotein, intermediate density lipoprotein, high density lipoprotein, their subfractions, and lipoprotein(a). Triglycerides in the database are directly measured using the Abbott ARCHITECT C-8000 system (Abbott Park, Illinois, USA). Lipid distributions in the database closely match those from the population-representative National Health and Nutrition Examination Survey (NHANES).
STUDY PROCEDURES:
This database was investigator-initiated. Only de-identified data reach the investigational site. The master database is housed at The Johns Hopkins Hospital in Baltimore, Maryland, and maintained by Drs. Jones and Martin. The current database (2nd harvest) includes 5,051,467 patients whose laboratory samples were collected from October 1, 2015 and June 30, 2019. Only electronic data, and not blood samples, are sent to Hopkins. The academic investigators have unrestricted access to study data, take responsibility for the accuracy of analyses, and have authority over manuscript preparation and submission.
VARIABLES:
The variables currently in the VLDL database are testing date, age, sex, fasting/nonfasting, and components of the VAP test. From these primary variables, many additional variables were derived for inclusion in the master database. Other analytes measured by validated assays in subsets of the VLDL database include apolipoprotein B (apoB), apolipoprotein A1 (apoAI), high-sensitivity C-reactive protein (hsCRP), homocysteine, uric acid, insulin, hemoglobin A1c, 25-hydroxy vitamin D, cystatin C, lipoprotein-associated phosphatase (Lp-PLA2), thyroid stimulating hormone (TSH), free T3 and T4, pro-brain natriuretic peptide (pBNP), direct bilirubin, creatine phosphokinase (CPK), creatinine and other components of the comprehensive metabolic panel, magnesium, and phosphate.
Conditions
- Lipid Disorders and Lipid Measurement
Sponsors & Collaborators
-
VAP Diagnostics Lab
collaborator UNKNOWN - lead OTHER
Principal Investigators
-
Steven R Jones, MD · Johns Hopkins University
-
Seth S Martin, MD, MHS · Johns Hopkins University
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2006-04-30
- Primary Completion
- 2026-04-30
- Completion
- 2030-04-30
Countries
- United States
Study Locations
More Related Trials
-
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects
NCT05569928 ·Status: UNKNOWN ·Phase: NA
-
A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
NCT04718961 ·Status: TERMINATED ·Phase: PHASE2
-
The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)
NCT01165060 ·Status: COMPLETED ·Phase: NA
-
Lysosomal Acid Lipase (LAL) Deficiency Registry
NCT01633489 ·Status: RECRUITING
-
Regulation of Sterol Homeostasis
NCT00018720 ·Status: COMPLETED
-
Serum Metabolics-based Method for Diagnosing Bile Acid Diarrhoea
NCT06548009 ·Status: COMPLETED
-
Identification of Undiagnosed Lysosomal Acid Lipase Deficiency
NCT01716728 ·Status: UNKNOWN ·Phase: NA
-
Clinical Outcome of Triheptanoin Treatment in Patients With Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) Treated Under Expanded Access Program
NCT03768817 ·Status: COMPLETED
-
Intravenous ACP-501 for Familial LCAT Deficiency (rhLCAT)
NCT04737720 ·Status: COMPLETED
-
Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders
NCT01373918 ·Status: TERMINATED ·Phase: PHASE4
-
A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)
NCT06575959 ·Status: COMPLETED ·Phase: PHASE1
-
PET/CT Scans Using the Tracer 11C-Csar, a Bile Acid Analog, to Depict and Visualize Cholestatic Disorders in Patients with Genetic Liver Disorders and Healthy Individuals
NCT06610695 ·Status: ENROLLING_BY_INVITATION
-
Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia
NCT02098278 ·Status: COMPLETED ·Phase: PHASE2
-
Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC)
NCT00571272 ·Status: SUSPENDED
-
Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT
NCT01879735 ·Status: COMPLETED ·Phase: PHASE1
-
SMOFLipid in Patients Who Are Intralipid Intolerant
NCT03054948 ·Status: WITHDRAWN ·Phase: PHASE4
-
Study to Re-assess and Re-confirm Data Previously Recorded About the Incidence and Severity of Acute Abdominal "Pancreatitis" Episodes in Lipoprotein Lipase Deficient (LPLD) Subjects Previously Enrolled on AMT Clinical Studies
NCT01448577 ·Status: UNKNOWN
-
The Use of High Bile-binding Foods to Reduce Upper Gastrointestinal Bile Acid Concentrations (Aim 2)
NCT07303868 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase Deficiency
NCT04227678 ·Status: RECRUITING ·Phase: NA
-
The Effect of a Probiotic on Hepatic Steatosis
NCT00099723 ·Status: TERMINATED ·Phase: PHASE1
-
A Pilot Study to Explore the Role of Gut Flora in Fatty Liver
NCT04160949 ·Status: WITHDRAWN
-
Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT04073368 ·Status: COMPLETED ·Phase: NA
-
Dietary Allowance of Methyl Donor Nutrients to Minimize Risks of Non-alcoholic Fatty Liver Progression
NCT05291104 ·Status: COMPLETED ·Phase: NA
-
Plasma Dihydroceramides Are Associated With Hepatic Steatosis in Type 1 and Type 2 Diabetes
NCT03447964 ·Status: COMPLETED
-
An Observational Study of Patients With Lysosomal Acid Lipase Deficiency/Cholesteryl Ester Storage Disease Phenotype
NCT01528917 ·Status: COMPLETED